ROIVANT SCIENCES LTD. Deferred Income Tax Expense (Benefit)
ROIVANT SCIENCES LTD. (ROIV) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-05-20
- ROIVANT SCIENCES LTD. deferred income tax expense (benefit) for fiscal 2026 was $0.00.
- ROIVANT SCIENCES LTD. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- ROIVANT SCIENCES LTD. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- ROIVANT SCIENCES LTD. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-03-31 | $0.00 10-K · filed 2026-05-20 |
| 2025-03-31 | $0.00 10-K · filed 2026-05-20 |
| 2024-03-31 | $0.00 10-K · filed 2026-05-20 |
| 2023-03-31 | $0.00 10-K · filed 2025-05-29 |
| 2022-03-31 | $0.00 10-K · filed 2023-06-28 |
| 2021-03-31 | $0.00 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |